RecruitingPhase 2NCT07209059

PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Research Center for Hematology, Russia
Principal Investigator
Evgeny E Zvonkov, MD, PhD
National Medical Research Center for Hematology
Intervention
Nivolumab(drug)
Enrollment
30 enrolled
Eligibility
18-60 years · All sexes
Timeline
20252028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07209059 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma

← Back to all trials